How Regeneron Pharmaceuticals Makes its Money: Revenue Breakdown

How Does Regeneron Pharmaceuticals Make its Money?

Regeneron Pharmaceuticals is a biotechnology company headquartered in Tarrytown, New York, founded in 1988 by scientists who have maintained a research-first culture throughout the company’s history. Regeneron discovers, develops, and commercialises medicines for serious diseases, primarily in ophthalmology, inflammatory and immune diseases, oncology, cardiovascular disease, and rare genetic conditions. The company is known for its VelociSuite gene-editing technology platform, which enables unusually rapid antibody drug discovery.

Regeneron’s revenue model is distinctive in large-cap biotech: the majority of its income does not come from direct drug sales but from collaboration revenue — primarily a profit-sharing arrangement with Sanofi for Dupixent, the company’s blockbuster immunology drug. In fiscal year 2025 (ended December 31, 2025), Regeneron generated $14.34B in total revenue, nearly flat (+1.0%) from $14.20B in FY2024. This near-flat total conceals a significant structural shift: direct product sales (primarily EYLEA) declined 17.3% due to biosimilar competition, while collaboration revenue (primarily Dupixent profit share) grew 21.0%.

Regeneron Pharmaceuticals (REGN) Business Model

Regeneron earns money through three channels:

1. Net product sales — Regeneron sells EYLEA (aflibercept), its anti-VEGF drug for wet age-related macular degeneration and other eye diseases, directly in the United States. It also sells EYLEA HD (a higher-dose formulation) and other specialty products. These are direct sales where Regeneron recognises the full net revenue after rebates and discounts.

2. Collaboration revenue — The largest and fastest-growing revenue channel. Under its partnership with Sanofi, Regeneron co-develops and co-commercialises multiple drugs including Dupixent (dupilumab), Kevzara (sarilumab), Praluent (alirocumab), and Libtayo (cemiplimab). The economics vary by drug but for Dupixent — the most important — Regeneron receives approximately 50% of global profits after expenses. This means Regeneron’s collaboration revenue reflects the underlying profitability of Dupixent globally, not just U.S. sales. Regeneron also earns collaboration revenue from Bayer related to EYLEA sales outside the United States.

3. Other product revenue — A catch-all category including milestone payments, technology licensing fees from the VelociSuite platform, and other contractual arrangements.

The Sanofi partnership structure creates an important accounting nuance: Dupixent’s global net product sales (reported by Sanofi) were approximately $16–17B annually, but Regeneron does not recognise those as revenue. Instead, Regeneron records the profit share on those sales as collaboration revenue — which is why “collaboration revenue” is structurally different from traditional product revenue.

Regeneron Pharmaceuticals Competitors

Regeneron Pharmaceuticals’s key competitors and comparable public companies in the biotechnology sector include Amgen, Eli Lilly, Novo Nordisk, and Pfizer. Each of these companies competes for market share, investor attention, and revenue in overlapping segments. See how Regeneron Pharmaceuticals stacks up by comparing their revenue breakdown, margins, and growth metrics.

Revenue Breakdown

FY2025 ended December 31, 2025. Financial data sourced from Regeneron SEC Filings.

Net Product Sales — 44% of Revenue

Net product sales in FY2025 were $6.31B, down 17.3% from $7.63B in FY2024. This decline is almost entirely attributable to EYLEA biosimilar competition. The original EYLEA formulation lost patent exclusivity, and biosimilar versions from multiple manufacturers entered the U.S. market in 2023–2024, rapidly eroding EYLEA’s market share and forcing price concessions. EYLEA had been Regeneron’s top-grossing direct product for over a decade.

Regeneron launched EYLEA HD (8mg aflibercept) as a next-generation successor with a longer dosing interval — patients can go up to 12–16 weeks between injections vs. 8 weeks for original EYLEA. EYLEA HD adoption has partially offset the original EYLEA decline, but not enough to prevent a significant net product sales reduction. This transition is one of the most important near-term dynamics in the business.

Collaboration Revenue — 51% of Revenue

Collaboration revenue grew to $7.33B in FY2025, up 21.0% from $6.06B in FY2024, and is now the largest revenue category. The dominant driver is the Dupixent profit share from Sanofi.

Dupixent (dupilumab) is a biologic drug that blocks IL-4 and IL-13 signalling pathways, making it effective against a wide range of Type 2 inflammatory diseases. It is approved for atopic dermatitis (eczema), asthma, chronic rhinosinusitis with nasal polyps, eosinophilic esophagitis, prurigo nodularis, and COPD with an eosinophilic phenotype — one of the broadest label expansions of any modern biologic. Dupixent’s global net product sales (as reported by Sanofi) exceeded $16B in 2024 and continue to grow rapidly as label expansions drive new patient starts.

Regeneron also earns collaboration revenue from:

• Libtayo (cemiplimab) — a PD-1 checkpoint inhibitor for skin cancers and lung cancer, co-developed with Sanofi
• Kevzara and Praluent — older drugs with smaller revenue contributions
• EYLEA ex-U.S. sales via Bayer — Bayer commercialises EYLEA and EYLEA HD outside the United States and pays Regeneron collaboration revenue on those sales

Other Product Revenue — 5% of Revenue

Other product revenue grew 36.4% to $703M in FY2025, driven by technology licensing arrangements (primarily the VelociSuite antibody discovery platform), contract manufacturing, and milestone payments from third-party collaborators using Regeneron’s technology.

Regeneron Pharmaceuticals (REGN) Income Statement

All values in millions USD unless noted.

Regeneron Pharmaceuticals (REGN) Key Financial Metrics

• Gross Margin: 85.4% — Among the highest in large-cap biotech. Regeneron sells biologic drugs with essentially no per-unit variable cost relative to selling price, driving exceptional gross margins. The 85% level has been stable for several years.
• Operating Margin: 25.0% — Down from 28.1% in FY2024, primarily because R&D spending jumped $741M (+14.2%) as Regeneron advanced its pipeline. Operating margin compression from R&D investment is generally viewed positively in biotech if the pipeline is productive.
• Revenue Growth: +1.0% — Near-flat headline growth masks the underlying transition: EYLEA declining, Dupixent collaboration revenue growing. Investors focus more on Dupixent trajectory than total company revenue.
• Free Cash Flow: $4,081M (28.5% margin) — Strong and growing. Regeneron converts a high percentage of profit to cash, reflecting the asset-light nature of collaboration revenue (Sanofi bears most of the Dupixent commercial costs).

Is Regeneron Profitable?

Yes, Regeneron is highly profitable. The company earned $4.51B in net income on $14.34B in revenue in FY2025, a net margin of 31.4%. Note that net income ($4.51B) significantly exceeds operating income ($3.58B) because Regeneron earned $1.70B in investment and other income — the company holds a large cash and investment portfolio that generates substantial returns.

Operating income declined slightly from $3.99B (FY2024) to $3.58B (FY2025) due to the $741M increase in R&D spending. This is the intended business model: reinvest drug profits aggressively into pipeline development. Regeneron’s R&D as a percentage of revenue (41.6% in FY2025) is exceptionally high even by biotech standards, reflecting founder-management’s commitment to scientific output over near-term margin maximisation.

Where Does Regeneron Spend its Money?

• Research & Development ($5,974M / 41.6% of revenue): Regeneron’s defining expense. The company runs one of the most productive pipelines in the industry, with dozens of clinical-stage programmes across oncology, cardiovascular, rare diseases, and neurology. Key pipeline assets include itepekimab (IL-33 antibody for COPD and asthma), linvoseltamab (BCMA/CD3 bispecific for multiple myeloma), fianlimab (PD-1 for melanoma and lung cancer), and a new obesity programme targeting PCSK9 and leptin receptor pathways.
• Selling, General & Administrative ($2,700M / 18.8% of revenue): Commercial operations in the U.S. for EYLEA HD and co-promotion of Libtayo, plus corporate overhead. SG&A actually declined from $2,954M in FY2024, reflecting cost discipline as Sanofi bears the primary commercial costs for Dupixent.
• Cost of Revenue ($2,101M / 14.6% of revenue): Manufacturing costs for EYLEA, EYLEA HD, and biologics supplied to Sanofi under the collaboration. Regeneron operates its own manufacturing facilities in New York, which gives it supply chain control but creates fixed cost infrastructure.

Regeneron Pharmaceuticals (REGN): What to Watch

1. EYLEA HD vs. biosimilar erosion — Original EYLEA is losing ground to biosimilars. The critical question is whether EYLEA HD uptake can fully offset the decline in the EYLEA franchise. Net product sales fell 17.3% in FY2025 — if EYLEA HD cannot arrest this, product revenue will continue declining.
2. Dupixent label expansion and peak sales estimate — Dupixent’s COPD approval opened an entirely new patient population. Analysts estimate Dupixent peak annual sales could reach $20–25B globally. The pace of COPD adoption and potential approvals in food allergy and alopecia areata are the key near-term growth drivers.
3. Sanofi collaboration economics — Regeneron’s profit-share arrangement with Sanofi is Dupixent-dependent. As Dupixent grows, so does the collaboration revenue line. Investors should monitor Sanofi’s quarterly reporting of Dupixent global sales for the most forward-looking signal on Regeneron’s largest revenue source.
4. Pipeline catalysts — Regeneron has several late-stage programmes that could provide significant revenue diversification over the next three to five years: linvoseltamab for multiple myeloma, fianlimab for melanoma, and early-stage obesity/cardiometabolic assets.
5. Investment income sustainability — $1.70B of non-operating income in FY2025 (vs. $844M in FY2024) boosted net income materially. This reflects gains on the company’s large investment portfolio in a rising market. This line can be volatile year-to-year.

Regeneron Pharmaceuticals (REGN) Financial Summary

Regeneron Pharmaceuticals (REGN) is a biotechnology company that generated $14.34B in total revenue in fiscal year 2025 (ended December 31, 2025), up 1.0% year-over-year. Collaboration revenue — primarily the Dupixent profit share from Sanofi — was the largest segment at $7.33B (+21.0%), while net product sales (primarily EYLEA and EYLEA HD) declined 17.3% to $6.31B amid biosimilar competition. The company earned $4.51B in net income at a 31.4% net margin, with gross margin of 85.4% and free cash flow of $4.08B. For a deeper look at Regeneron’s revenue breakdown, business model, and financial performance, review the detailed analysis above.